Can-Fite BioPharma Ltd (CANF) has released an update.
Can-Fite BioPharma Ltd. has reported a decrease in annual revenues and a significant reduction in net loss for 2023, highlighting clinical advancements in their drug candidates Piclidenoson and Namodenoson for various diseases. Ewopharma has expanded its distribution agreement with Can-Fite to include the marketing of Namodenoson for pancreatic cancer, while Piclidenoson continues to show promise in a pivotal Phase III study for psoriasis. The company’s financial position is stable with a slight increase in cash reserves compared to the previous year.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
